Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 3/20 | 0.57 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17409789 | 0.88 | DRD4 (0.51) | WNT1GSK3BDYRK1ADRD2DRD4 | |
| SCHEMBL17409803 | 0.85 | GSK3B (0.55) | WNT1GSK3BDYRK1ADRD2DRD4 | |
| SCHEMBL15986890 | 0.85 | GSK3B (0.54) | WNT1GSK3BDYRK1APOLBMEN1 | |
| SCHEMBL21676901 | 0.85 | KDM4E (0.58) | WNT1GSK3BDYRK1ADRD2DRD4 | |
| SCHEMBL17409785 | 0.85 | DRD4 (0.56) | WNT1GSK3BDYRK1ADRD2DRD4 | |
| SCHEMBL17450652 | 0.81 | RAB9A (0.57) | WNT1GSK3BDYRK1ARAB9AMAPT | |
| SCHEMBL17450650 | 0.80 | RAB9A (0.56) | WNT1GSK3BDYRK1ARAB9AMAPT | |
| SCHEMBL17450648 | 0.79 | ALDH1A1 (0.60) | WNT1GSK3BDYRK1ARAB9AMAPT | |
| SCHEMBL18998184 | 0.78 | RAB9A (0.53) | DRD2DRD4RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL21676988 | 0.78 | RAB9A (0.53) | DRD2DRD4RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | TBK1, TBKBP1, TYMS | WNT1 670/4885GSK3B 328/4885DYRK1A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.